



OFFICIAL

RECEIVED
CENTRAL FAX CENTER
AUG 05 2004

Facsimile Cover Sheet

To: Commissioner for Patents
U. S. Patent and Trademark Office

Fax: (703) 872-9306

From: Roberta P. Saxon, Ph. D.
Reg. No. 43,087
Patent Department

Company: Theravance, Inc.

Telephone: 650-808-3764

Fax: 650-808-6078

Date: August 5, 2004

of pages: 4 (including this page)

Re: Supplemental Information Disclosure Statement

U. S. Serial Number 10/627,555

Attorney Docket No: P-154-US1

Examiner: Shailendra Kumar

Group Art Unit: 1621

Attached are the following documents:

1. Supplemental Information Disclosure Statement (2 pages)
2. Information Disclosure Statement by Applicant (Form PTO/SB/08a) - 1 page

Certificate of Facsimile Transmission

Facsimile Number: (703) 872-9306

I hereby certify that this correspondence is being transmitted on the date shown below via facsimile to Commissioner for Patents, United States Patent and Trademark Office at the facsimile number indicated above.

By: Barbara Bryant
Barbara Bryant

Date: August 5, 2004

Notice of Confidentiality

The following transmittal contains confidential information intended exclusively for the above-named person. Use, copying, distribution or disclosure of information transmitted in error is strictly prohibited. Please call Theravance, Inc. at the above number if you have received this fax in error, and either destroy or return the enclosures to us.

PRIVILEGED AND CONFIDENTIAL

901 Gateway Blvd., South San Francisco, CA 94080; Tel. (650) 808-6000; Fax (650) 808-6078

OFFICIAL

RECEIVED 002
CENTRAL FAX CENTER

AUG 05 2004

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being transmitted via facsimile number (703) 872-9306 to Commissioner for Patents, United States Patent and Trademark Office, on the date shown below:

By: Barbara Bryant Date: August 5, 2004
Barbara Bryant

Patent
Attorney's Docket No. P-154-US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
)	
MORAN et al.)	Group Art Unit: 1621
)	
Application No.: 10/627,555)	Examiner: Shailendra Kumar
)	
Filed: July 25, 2003)	
)	
For: CRYSTALLINE B ₂ ADRENERGIC)	
RECEPTOR AGONIST)	
)	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 CFR §1.56, Applicants hereby submit the following information in conformance with CFR §§1.97 and 1.98. Enclosed herewith is form PTO/SB/08a which lists documents for consideration by the Examiner.

The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 C.F.R. §1.97(g)), or as an admission that the information cited is, or is considered to be, material to patentability (37 C.F.R. §1.97(h)).

Attorney Docket No. P-154-US1
Application Serial No.: 10/627,555

Page 1 of 2

Additionally, Applicants hereby bring to the Examiner's attention the following commonly assigned application:

U. S. Serial No. 10/854,405, filed on May 26, 2004.

Copies of the U.S. patent and patent application publication cited on the accompanying PTO Form PTO/SB/08a have been omitted in accordance with the notice published August 5, 2003 in the Official Gazette 55, stating that the requirement under 37 CFR 1.98 (a)(2) for submitting such copies has been waived for U.S. national patent applications filed after June 30, 2003.

Consideration of the listed documents is respectfully requested. Additionally, the Examiner is respectfully requested to return an initialed copy of the enclosed form PTO/SB/08a to Applicants.

This Information Disclosure Statement is being filed before the mailing date of a first official action on the merits for this application and therefore, no fee or certification is required under 37 CFR §1.97(b). In the event that an Office Action is mailed prior to receipt of this paper, the Commissioner is hereby authorized to charge the requisite fees under 37 CFR §1.97(c) for submission of this paper to Deposit Account No. 50-0344.

Should there be any questions concerning the cited documents, the Examiner is encouraged to telephone the undersigned agent for Applicants at (650) 808-3764 (direct).

Respectfully submitted,

THERAVANCE, INC.

Date: August 5, 2004

By: Roberta P. Saxon

Roberta P. Saxon, Ph.D.
Registration No. 43,087

THERAVANCE, INC.
901 Gateway Boulevard
South San Francisco, CA 94080
Tel: (650) 808-6000
Fax: (650) 808-6078

Attorney Docket No. P-154-US1
Application Serial No.: 10/627,555

Page 2 of 2

